单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
潜在生物标志物：在过继性细胞治疗中识别强效肿瘤特异性 T 细胞
英文原题：Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.
查看英文原题
Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤特异性T细胞（TSTs）是个性化TIL（肿瘤浸润淋巴细胞）过继细胞治疗（ACT）成功的关键组成部分。因此，选择一种通用生物标志物来筛选不同肿瘤类型中的TSTs，并通过体外扩增至临床数量水平，可以产生最大的治疗效果。然而，关于TSTs共享生物标志物的研究尚未实现。本综述总结了过去5年中在几种肿瘤类型中研究的若干TSTs生物标志物的异同，以及联合生物标志物的优势。此外，综述讨论了当前生物标志物可能的不足，并强调了利用细胞间相互作用准确识别TSTs的策略。最后，探讨了TSTs在个性化TIL-based ACT中更广泛临床应用的发展。
展开英文摘要原文
Tumor-specific T cells (TSTs) are essential components for the success of personalized tumor-infiltrating lymphocyte (TIL)-based adoptive cellular therapy (ACT).
Therefore, the selection of a common biomarker for screening TSTs in different tumor types, followed by ex vivo expansion to clinical number levels can generate the greatest therapeutic effect.
However, studies on shared biomarkers for TSTs have not been realized yet. The present review summarizes the similarities and differences of a number of biomarkers for TSTs in several tumor types studied in the last 5 years, and the advantages of combining biomarkers.
In addition, the review discusses the possible shortcomings of current biomarkers and highlights strategies to identify TSTs accurately using intercellular interactions.
Finally, the development of TSTs in personalized TIL-based ACT for broader clinical applications is explored.
论文信息
- 作者
- Ge W、Dong Y、Deng Y、Chen L、Chen J、Liu M、Wu J、Wang W
- 单位
- Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36451828 · DOI 10.3389/fimmu.2022.1003626
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →